Search Results

Hemogenyx Pharmaceuticals plc, the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress.

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting held earlier , all resolutions were duly passed on a show of hands.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC, an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares at a price of US$0.075 per share for the total sum of $830,000.